Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer
about
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repairSTRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1BRCAness: finding the Achilles heel in ovarian cancerOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - AnDNA methylation changes in epithelial ovarian cancer histotypes.Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancerPALB2: the hub of a network of tumor suppressors involved in DNA damage responsesAugmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancersmiR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axisMutational landscape and significance across 12 major cancer typesThe causes and consequences of genetic heterogeneity in cancer evolutionAssessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group StudySystematically Prioritizing Functional Differentially Methylated Regions (fDMRs) by Integrating Multi-omics Data in Colorectal CancerGermline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the TumorThe role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer PatientsA Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerCirculating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerGermline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.Personalising pancreas cancer treatment: When tissue is the issue.A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers.Transcriptional profiling and dynamical regulation analysis identify potential kernel target genes of SCYL1-BP1 in HEK293T cells.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinomaHigh levels of genomic aberrations in serous ovarian cancers are associated with better survival.A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapyPrevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysisTrabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
P2860
Q24317107-BD69C414-B2B9-4133-A303-4A44BDD05817Q24600363-7E7CC45B-9EBF-4499-A2EA-CA077C99A9BEQ24630872-68FCD73E-0519-4621-B983-958704A9BD99Q26777846-05589ADD-B20C-4D4E-B0E0-6762DB600781Q26780387-B68A27AA-C8C9-4675-BBD1-9BBF051D41B2Q26783551-CD45F37D-39BC-49C5-83B2-F36755576D1FQ27024235-7E3C3940-653E-4604-ACBC-3B478B46BD4BQ27302763-941DBA4D-405E-4C56-B11C-908A50A10F4DQ27690722-98262102-8606-4057-90E1-7E2F0A59FC04Q27851709-8501A0C4-0D43-4CB3-B996-68B00C3DBAF7Q27852185-C03E1B7E-687C-41F4-A6F2-FA168241C8ABQ27852671-2FC15115-20AA-4F06-B6D7-80A39C56A623Q28073673-5F57956E-2CC7-4B58-9E69-7039AE5B5CFDQ28082679-98FFB7C0-BA34-4E2D-BFEE-ADF09FE8D51AQ28243398-D01367BA-41C8-42C3-8500-978C7FD19F5CQ28262260-B1807CA8-D2E9-42FA-B3CF-DC140AD10DDCQ28267333-608A03FD-2410-4CE1-947B-13F14FC410ADQ28300353-CE351CB0-6996-45E9-8EE9-F9308403E9B0Q29615848-F2CC00FD-EF5D-4BEF-8B4B-4090664942A7Q30417640-FC065D84-E252-49BB-B20E-0575DD382999Q30659867-58B3F123-C829-436C-AD0A-0B534FC13714Q33458308-CB8E0BF0-631F-4C09-9BE4-46A3F2585E01Q33553318-B583B5BC-7537-40F2-A207-FA10F23E4E17Q33584055-AE4C049F-C07D-4A6A-9D6F-531C30027E2AQ33606561-08B4CACD-00D9-49FB-ABF2-D3486AA98AD2Q33640472-4C3DC7DD-5E48-49A1-8878-BD9727F7FC3BQ33704050-EF3062FC-8151-48D3-9224-B80AA719FDCFQ33735109-8007618F-37C0-4055-AEFE-92B104D8685DQ33801384-8301987F-73A3-4269-A7ED-964D744210CEQ33983698-2BCA1029-D90B-4F27-AFD7-CD9B0F0A9A5EQ34263334-1582AF3C-91A4-462B-B7E3-001F84E5B0FEQ34305493-A3FEB0FE-372C-4DE5-8A4F-FCA97A078337Q34380980-2114CA78-777C-4A64-88CF-5063B82C6079Q34455481-FC9430DE-6079-4034-BEF7-99BF9613C257Q34552129-3239C9FD-3BB5-41EC-85FB-A2A522336062Q34571142-8595E0E6-9CE7-4DEB-B414-6D15C4B23FA5Q34599539-734D676B-CEA1-4988-A7F0-F7F0485C5730Q34639149-849C0FAF-5877-43E9-A8F2-720BB66A10C0Q34860429-D84869B3-3CC3-46FA-A8FC-841484375C09Q34996149-79F55589-8C8A-41F5-9DAA-02A4F93FF318
P2860
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@ast
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@en
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@nl
type
label
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@ast
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@en
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@nl
prefLabel
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@ast
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@en
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@nl
P2093
P2860
P921
P356
P1476
Association of BRCA1 and BRCA2 ...... n patients with ovarian cancer
@en
P2093
Anil K Sood
Ilya Shmulevich
Kenneth Hess
P2860
P304
P356
10.1001/JAMA.2011.1456
P407
P577
2011-10-01T00:00:00Z